L

Lupin Pharmaceuticals

Global pharmaceutical manufacturer and distributor

Systems Engineer

Full-TimeDeadline 1/22/27
No salary listed
Mid
Bachelor's
Coral Springs, FL, USA
In Person
IT OperationsSystem Administration

About the job

Requirements
  • Working knowledge of networking concepts including routing, switching, VLANs, VPNs, DHCP, and DNS.
  • Hands-on experience with firewalls, routers, switches, Wi-Fi devices at Layer 2 and Layer 3, Windows Server operating systems, and VMware virtualization hypervisors.
  • Working knowledge of Microsoft 365 and Microsoft Teams Rooms conferencing systems.
  • Knowledge of Cisco, Juniper, and Aruba technologies and architectures, including cloud and cloud security, network segmentation, patching, next-generation antivirus, Avaya voice over IP, and Teams-based conferencing systems.
  • Experience managing and maintaining servers, LAN, IP phone, and WAN systems; switches, routers, access points, and VPNs; and knowledge of IT-OT network segregation.
  • Three to five years of hands-on experience with the stated technologies.
  • Current or desired certification knowledge including JNCIE-ENT, JNCIE, CCIE, CCNP, CEH, CISSP, or MCSA.
Responsibilities
  • Respond to, manage, and escalate technical support requests through the ticketing system, telephone, email, or remote support tools.
  • Support business-user endpoint devices, including laptops, desktops, smartphones, tablets, iPads, and video-conferencing services, directly or through remote support tools.
  • Ensure compliance with site-specific IT standard operating procedures.
  • Manage and maintain analytical laboratory and computerized manufacturing control systems in a Good Manufacturing Practice environment according to regulatory requirements.
  • Manage server, network, and telecommunications infrastructure in Lupin's United States and Canada sites.
  • Work on security tools, technologies, and platforms such as Zscaler, Zero Trust, and privileged access management.
  • Maintain Juniper network infrastructure, including configuration and maintenance, and own responsibility for multi-site Aruba Wi-Fi infrastructure.
  • Oversee timely repair or replacement of faulty endpoint devices, network hardware, and appliances.
  • Maintain hardware inventories for endpoint devices, servers, and network equipment.
  • Handle day-to-day end-user support tickets and provide white-glove information technology support to VIP users.
  • Work with central information technology teams to resolve issues involving centrally managed platforms.
  • Own end-to-end responsibility for resolving issues in a timely manner.
  • Monitor server and network infrastructure and perform corrective actions on observed events.
  • Provide updates on infrastructure health and corrective or preventive actions.
  • Maintain current inventories of endpoint, server, and network devices.
Desired Qualifications
  • A bachelor's degree in information technology or a similar field.
  • Preferred certifications include current JNCIE-ENT, JNCIE, CCIE, CCNP, CEH, CISSP, or MCSA certification.

About the company

Lupin Limited develops and sells branded and generic medicines, complex generics, biotechnology products, and active pharmaceutical ingredients across over 100 markets. It brings medicines to patients by designing formulations and APIs, manufacturing at 15 sites, and distributing through a global network, supported by 7 research centers. Its integrated model combines a broad product portfolio with dedicated manufacturing, diagnostics, digital health, and manufacturing services to serve multiple therapeutic areas. Its goal is to improve patient health outcomes by expanding access to high-quality medicines and strengthening its global research, manufacturing, and digital capabilities.

Company Size

10,001+

Company Stage

IPO

Headquarters

Mumbai, India

Founded

1968

Get referred to Lupin Pharmaceuticals

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q1 FY2027 sales rose 33.3% to INR 82,172 million on August 6, 2026.
  • September 4, 2026 FDA approval for modafinil widens Lupin’s U.S. CNS portfolio.
  • August 20, 2026 YUVEZZI deal opens Europe, UK, Switzerland, Norway, and Iceland.

What critics are saying

  • Management warned August 2026 of U.S. revenue moderation from tolvaptan and mirabegron competition.
  • Pithampur Unit II still carries OAI status, keeping FDA remediation pressure alive into 2027.
  • A serious U.S. manufacturing shutdown at Somerset or Pithampur would freeze launches and margins.

What makes Lupin Pharmaceuticals unique

  • Lupin combines first-to-file generics, biosimilars, and specialty ophthalmology after VISUfarma’s 2026 acquisition.
  • Ranluspec became June 2026’s only interchangeable ranibizumab biosimilar in vials and syringes.
  • FY2026 filings reached 430 ANDAs, signaling a durable U.S. scale machine.

Help us improve and share your feedback! Did you find this helpful?

Growth & Insights and Company News

Headcount

6 month growth

15%

1 year growth

15%

2 year growth

15%
PR Newswire
Aug 20th, 2026
Lupin partners with Tenpoint to bring presbyopia eye drop YUVEZZI to Europe and UK

Lupin's subsidiary VISUfarma has secured exclusive rights to commercialise YUVEZZI, a once-daily presbyopia eye drop, across the EU, UK, Switzerland, Norway, and Iceland through a licensing agreement with Tenpoint Therapeutics' subsidiary Visus Therapeutics. Under the deal, VISUfarma will make a strategic investment in Visus. Tenpoint and Visus will be eligible for regulatory and commercial milestone payments plus tiered royalties based on net sales. YUVEZZI is the first FDA-approved dual-agent eye drop for presbyopia, combining carbachol and brimonidine tartrate. The treatment addresses a condition affecting approximately 2 billion people globally. The partnership strengthens Lupin's vision care franchise following its acquisition of VISUfarma. Tenpoint is advancing US commercialisation and has submitted regulatory applications in the UK, with plans for additional markets worldwide.

PR Newswire
Aug 17th, 2026
Lupin receives US FDA approval for generic Pitolisant tablets

Lupin Limited has received final approval from the US Food and Drug Administration for its generic Pitolisant Tablets in 4.45 mg and 17.8 mg strengths. The FDA approved Lupin's tablets as bioequivalent to Wakix for the indications in the approved labelling. Lupin is a Mumbai-based global pharmaceutical company that distributes products in over 100 markets. The company specialises in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates 15 manufacturing sites and six research centres globally, employing over 26,000 professionals.

PR Newswire
Jul 30th, 2026
Lupin launches generic Sugammadex injection in US after FDA approval

Lupin Limited has received US FDA approval and launched Sugammadex Injection in the United States. The product is available in two strengths: 200 mg/2 mL and 500 mg/5 mL single-dose vials. Sugammadex Injection is bioequivalent to Merck's Bridion Injection. It is indicated for reversing neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults and paediatric patients aged 2 years and older undergoing surgery. Lupin is a Mumbai-based pharmaceutical company with products distributed in over 100 markets. The firm specialises in branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. It operates 15 manufacturing sites and 7 research centres globally, employing over 26,000 professionals.

Multibagg AI
Jul 2nd, 2026
Lupin subsidiary to acquire 43.38% stake in Philippines' MPPI for up to $39.6M by May 2026

Lupin Ltd announced its subsidiary Nanomi B.V. will acquire a 43.38% stake in Multicare Pharmaceuticals Philippines Inc for up to $39.6 million in cash, with completion expected by end-May 2026. The deal involves purchasing 11,794,497 shares from existing shareholders to strengthen Lupin's presence in the Philippines. Separately, MPPI executed a buyback of 2,813,811 shares using retained earnings. As Nanomi did not participate, its holding automatically increased from 51% to 56.28%. MPPI reported turnover of PHP 2,096.60 million and net worth of PHP 1,265.50 million as of 31 March 2025. Lupin's shares fell 2.52% in early trade on 2 April following the announcement, trading at ₹2,216.20 on BSE.

PR Newswire
Jun 26th, 2026
Lupin receives tentative US FDA approval for generic Enzalutamide tablets

Lupin Limited has received tentative approval from the US FDA for its Enzalutamide Tablets in 40mg, 80mg, 120mg and 160mg strengths. The 40mg and 80mg versions were approved as bioequivalent to Astellas' Xtandi Tablets. Whilst Xtandi traditionally comes in 40mg and 80mg strengths, Lupin's tentatively approved 120mg and 160mg formulations will offer healthcare providers and patients additional dosing options. The Mumbai-based pharmaceutical company distributes products in over 100 markets globally. Lupin operates 15 manufacturing sites and seven research centres worldwide, employing over 24,000 professionals. The company specialises in branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients across multiple therapy areas including respiratory, cardiovascular and anti-diabetic treatments.